Zacks Research Issues Optimistic Outlook for AbbVie Earnings

Key Points

• Zacks Research has raised its Q2 2027 EPS estimate for AbbVie to $3.85, slightly above the prior estimate of $3.84, while the company’s full-year earnings consensus stands at $12.31 per share.
• AbbVie recently reported quarterly earnings of $2.97 per share, missing the analysts' consensus estimate by ($0.27), but generated revenues of $15.42 billion, exceeding expectations.
• The company declared a quarterly dividend of $1.64 per share, representing an annualized dividend yield of 3.0%, with a reported dividend payout ratio of 312.38%.

AbbVie Inc. (NYSE:ABBV - Free Report) - Research analysts at Zacks Research lifted their Q2 2027 earnings per share (EPS) estimates for AbbVie in a research report issued on Thursday, September 18th. Zacks Research analyst Team now forecasts that the company will earn $3.85 per share for the quarter, up from their previous forecast of $3.84. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie's FY2027 earnings at $15.25 EPS.

Other equities research analysts also recently issued research reports about the company. Daiwa Capital Markets upgraded AbbVie from a "neutral" rating to an "outperform" rating and set a $214.00 target price on the stock in a research report on Thursday, August 7th. Bank of America upped their target price on AbbVie to $204.00 and gave the stock a "hold" rating in a research report on Monday, June 9th. Wells Fargo & Company increased their target price on shares of AbbVie from $240.00 to $260.00 and gave the company an "overweight" rating in a research note on Friday, September 12th. Berenberg Bank raised shares of AbbVie from a "hold" rating to a "buy" rating and boosted their price objective for the company from $170.00 to $270.00 in a research report on Wednesday. Finally, Cantor Fitzgerald raised their target price on shares of AbbVie from $215.00 to $245.00 and gave the company an "overweight" rating in a research report on Monday, September 15th. Four analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $222.68.

AbbVie Stock Up 0.1%

NYSE:ABBV traded up $0.30 during mid-day trading on Friday, hitting $222.29. 14,371,957 shares of the company's stock traded hands, compared to its average volume of 4,244,925. The company has a fifty day moving average of $203.12 and a 200 day moving average of $194.89. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The company has a market capitalization of $392.69 billion, a P/E ratio of 105.85, a P/E/G ratio of 1.33 and a beta of 0.53. AbbVie has a twelve month low of $163.81 and a twelve month high of $223.49.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. During the same quarter in the previous year, the business earned $2.65 earnings per share. AbbVie's revenue was up 6.6% compared to the same quarter last year.

Institutional Trading of AbbVie

A number of institutional investors and hedge funds have recently bought and sold shares of ABBV. Vanguard Group Inc. lifted its holdings in AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company's stock worth $32,910,186,000 after purchasing an additional 3,380,842 shares during the last quarter. Geode Capital Management LLC increased its position in AbbVie by 2.4% in the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company's stock worth $7,240,169,000 after buying an additional 924,761 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in AbbVie by 6.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company's stock worth $4,970,848,000 after purchasing an additional 1,517,222 shares during the period. Norges Bank bought a new stake in shares of AbbVie in the 2nd quarter worth approximately $4,288,200,000. Finally, Northern Trust Corp increased its stake in shares of AbbVie by 0.9% in the 1st quarter. Northern Trust Corp now owns 22,013,920 shares of the company's stock worth $4,612,357,000 after purchasing an additional 189,294 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the sale, the executive vice president owned 58,247 shares in the company, valued at $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares of the company's stock, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.25% of the company's stock.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Wednesday, October 15th will be issued a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a yield of 3.0%. The ex-dividend date is Wednesday, October 15th. AbbVie's dividend payout ratio is presently 312.38%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.